CDEK
← All drugs Report issue

anacetrapib

Small moleculeexperimental

Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck. — Wikipedia

Clinical trial activity

15 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
10
Phase 3
8
Phase 4
0

Earliest trial started Jun 1, 2006 (NCT00325455)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C
Mol. weight
637.51 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • anacetrapib
  • anacetrapib
  • anacetrapib
  • anacetrapib
  • mk0859
  • mk0859
  • mk0859
  • mk 0859
  • mk-0859

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01841684Phase 3Jun 1, 2013Merck
NCT01860729Phase 3May 1, 2013Merck
NCT01824238Phase 3May 1, 2013Merck
NCT01760460Phase 3Mar 14, 2013Merck
NCT01717300Phase 3Nov 6, 2012Merck
NCT01524289Phase 3Feb 1, 2012Merck
NCT01252953Phase 3Jun 1, 2011Merck, University of Oxford
NCT01122667Phase 1Jun 1, 2010Merck
NCT01114490Phase 1May 1, 2010Merck
NCT00990808Phase 1Nov 1, 2009Merck
NCT00977288Phase 2Sep 1, 2009Merck
NCT00685776Phase 3Mar 1, 2008Merck
NCT00565292Phase 1Jul 1, 2006Merck
NCT00565006Phase 1Jul 1, 2006Merck
NCT00325455Phase 2Jun 1, 2006Merck
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit151432006
University of OxfordAcademic/Hospital1112011
2 organizations
Page 1 / 1